Mouse Model of Acute to Chronic Kidney Disease Transition Induced by Renal Ischemia/Reperfusion Injury
February 10th, 2026
536 views
This article presents an ischemic CKD model using unilateral renal IRI with contralateral nephrectomy performed one day prior to sample collection; this protocol enables serum-based functional assessment, high survival, and reproducible CKD pathology at 28 and 42 days, providing a versatile platform for mechanistic and interventional studies.
Overview
This article presents a dorsal surgical approach for inducing renal ischemia–reperfusion injury (IRI) in mice, providing a robust and reproducible model for studying the transition from acute kidney injury (AKI) to chronic kidney disease (CKD). The protocol combines unilateral renal IRI with contralateral nephrectomy performed one day prior to sample collection, optimizing both survival and consistency of injury for mechanistic investigations of CKD progression.
Key Study Components
Area of Science
- Nephrology
- Experimental surgery
- Animal models of kidney disease
Background
- Renal IRI is a standard model for studying AKI and its progression to CKD in mice.
- Conventional protocols often compromise either functional assessment or animal survival.
- Existing models struggle to balance reproducibility, injury severity, and long-term survival.
- Reliable models are needed for mechanistic studies of CKD development.
Purpose of Study
- To establish a reproducible and robust mouse model for the AKI-to-CKD transition.
- To minimize variability and maximize survival in renal IRI experiments.
- To enable comprehensive functional and pathological assessment of kidney injury and fibrosis.
Methods Used
- Dorsal surgical approach for kidney access and IRI induction.
- Unilateral renal IRI combined with contralateral nephrectomy performed one day before sample collection.
- Serum-based functional evaluation using BUN and creatinine measurements.
- Histological assessment of interstitial fibrosis via Masson's trichrome staining and CKD marker gene analysis at 28 and 42 days post-injury.
Main Results
- The dorsal approach allows straightforward kidney access and reduces intra-abdominal manipulation.
- Combining unilateral IRI with delayed nephrectomy yields nearly 100% survival and consistent injury severity.
- This protocol avoids the variability of bilateral injury models and the high mortality of early nephrectomy.
- Functional and histological assessments provide complementary insights into kidney impairment and fibrosis development.
Conclusions
- This protocol offers a reliable and versatile mouse model for studying ischemic CKD progression.
- It enables mechanistic investigations by balancing reproducibility, survival, and comprehensive assessment.
- The approach is suitable for long-term studies of kidney injury and fibrosis.
Frequently Asked Questions
What is the main advantage of the dorsal approach for renal IRI in mice?
The dorsal approach provides straightforward access to the kidneys, minimizes intra-abdominal manipulation, and improves reproducibility and survival rates in renal IRI models.
How does this protocol improve survival compared to traditional models?
By performing contralateral nephrectomy one day prior to sample collection rather than earlier, the protocol achieves nearly 100% survival while maintaining consistent injury severity.
Why is unilateral IRI combined with nephrectomy preferred over bilateral IRI?
Unilateral IRI with nephrectomy reduces variability and avoids the inconsistencies and higher mortality associated with bilateral injury models.
What functional assessments are used in this protocol?
Serum blood urea nitrogen (BUN) and creatinine levels are measured to evaluate kidney function after injury.
How is kidney fibrosis assessed in this model?
Interstitial fibrosis is quantified using Masson's trichrome staining for collagen deposition and analysis of CKD marker gene expression at 28 and 42 days post-injury.
What are the main applications of this mouse model?
This model is ideal for mechanistic studies of the AKI-to-CKD transition, evaluation of therapeutic interventions, and investigation of kidney fibrosis and functional impairment.
Executive Industry Relevance
Reliable modeling of the acute to chronic kidney disease (CKD) transition is critical for de-risking nephrology drug discovery and enabling predictive preclinical evaluation. This dorsal approach mouse model delivers consistent injury severity and high survival, supporting robust mechanistic studies and translational biomarker development. Its reproducibility and functional readouts position it as a foundational tool for portfolio triage and target validation in renal disease pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of therapeutic hypotheses underlying AKI-to-CKD progression.
- Supports mechanistic de-risking by providing a controlled, reproducible injury model.
- Facilitates functional target validation through quantitative serum and histological endpoints.
Screening & Assay Development
- Provides a validated in vivo system for evaluating candidate interventions targeting kidney injury and fibrosis.
- Delivers standardized, quantitative outputs (BUN, creatinine, fibrosis markers) for assay development.
- Ensures reproducibility and scalability for screening compound efficacy in disease-relevant settings.
Translational & Preclinical Research
- Aligns with translational biomarker strategies by integrating functional and histopathological readouts.
- Enables continuity from discovery through preclinical validation of anti-fibrotic or renoprotective agents.
- Supports risk-adjusted advancement decisions by modeling long-term CKD outcomes.
Pipeline & Workflow Integration
This model bridges early discovery and preclinical validation by enabling hypothesis-driven studies of AKI-to-CKD transition and therapeutic intervention assessment.
- Discovery Biology: Supports null hypothesis testing and mechanistic pathway clarification in kidney injury progression.
- Screening: Provides reproducible, quantitative endpoints for compound evaluation and assay standardization.
- Analytics: Enables statistical comparison of functional and fibrotic outcomes across experimental groups.
- Translational Research: Facilitates biomarker alignment and preclinical continuity for CKD drug candidates.
- Enterprise Reuse: Offers a robust, reusable platform for diverse nephrology R&D programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in CKD research.
- Operational Value: Standardizes injury induction and readouts, improving reproducibility and scalability.
- Strategic Value: Enables informed go/no-go decisions and capital-efficient portfolio management.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of renal disease assets.
Implementation Considerations
- Requires surgical expertise in dorsal kidney access and nephrectomy procedures.
- Needs access to serum chemistry analyzers and histological staining infrastructure.
- Demands cross-team standardization of injury induction and sample collection timing.
- Adaptable to various genetic or pharmacological intervention studies in mice.
- Limitations include species-specific responses and the need for careful post-surgical monitoring.
Biopharma FAQs
Why does null hypothesis testing matter for AKI-to-CKD target validation?
Null hypothesis testing using this model enables rigorous evaluation of whether candidate interventions or genetic modifications alter the progression from acute kidney injury to chronic disease, supporting robust target validation and reducing mechanistic uncertainty in early discovery.
How does independent variable isolation fit the renal IRI discovery pipeline?
The protocol's unilateral IRI with delayed nephrectomy design isolates the effects of injury and intervention, minimizing confounding variables and enabling clear attribution of observed outcomes to specific experimental manipulations within the discovery pipeline.
What do quantitative BUN and creatinine measurements enable in CKD studies?
Quantitative serum BUN and creatinine measurements provide objective, reproducible endpoints for assessing kidney function, enabling direct comparison of intervention efficacy and supporting data-driven advancement decisions in CKD research programs.
Why are replication requirements critical for cross-functional nephrology teams?
Replication of injury severity and survival across cohorts ensures that functional and histological findings are robust, facilitating cross-functional collaboration and confidence in data used for target prioritization and preclinical candidate selection.
What statistical analysis capabilities are required before CKD model implementation?
Teams must be equipped to perform statistical comparisons of functional and fibrotic endpoints, including group-wise analysis of BUN, creatinine, and fibrosis markers, to ensure reliable interpretation and actionable insights from model outputs.
